[Disclosure] Celltrion (068270) – Application for Phase 3 Clinical Trial Plan for CT-P55 (Cosentyx Biosimilar) in the U.S. / 2024-07-01
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced that it has submitted an application for a global Phase 3 clinical trial plan to the U.S. Food and Drug Administration (FDA) to evaluate the efficacy and safety of CT-P55 compared with Cosentyx in patients with plaque psoriasis. 📊 [Key Disclosure Details & Financial…